Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acetylcholinesterase Inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Acetylcholinesterase Inhibitor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-002007-33 Sponsor Protocol Number: A2581078 Start Date*: 2004-11-25
    Sponsor Name:Pfizer Inc.
    Full Title: An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhib...
    Medical condition: Alzheimer Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004765-40 Sponsor Protocol Number: 14863A Start Date*: 2014-03-31
    Sponsor Name:H. Lundbeck A/S
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000445-39 Sponsor Protocol Number: ACI-24-1801 Start Date*: 2018-06-19
    Sponsor Name:AC Immune SA
    Full Title: A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild ...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001174-25 Sponsor Protocol Number: NC501/SC01904 Start Date*: Information not available in EudraCT
    Sponsor Name:Neurocure Ltd
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION
    Medical condition: Healthy subjects who are smokers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001564-30 Sponsor Protocol Number: RA101495-02.301(RAISE) Start Date*: 2020-03-31
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014388-38 Sponsor Protocol Number: NEUAZ1 Start Date*: 2009-09-28
    Sponsor Name:Neurim Pharmaceuticals Ltd
    Full Title: A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) tre...
    Medical condition: Insomnia in patients with mild to moderate Alzheimers Disease.
    Disease: Version SOC Term Classification Code Term Level
    10. 10036701 Primary Insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001967-11 Sponsor Protocol Number: PBD01071 Start Date*: 2015-02-05
    Sponsor Name:Probiodrug AG
    Full Title: A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease
    Medical condition: Early Stage Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) SE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005292-17 Sponsor Protocol Number: TRx-237-008 Start Date*: 2012-10-02
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of LMTM in Subjects with Mild to Moderate Alzheimer’s Disease on Pre-Existing Stable Acetylcholinesterase Inhibi...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020008-31 Sponsor Protocol Number: ACP-103-019 Start Date*: 2013-10-25
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease
    Medical condition: Psychosis associated with Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005260-14 Sponsor Protocol Number: ACI-91-0801 Start Date*: 2008-11-26
    Sponsor Name:AC Immune SA
    Full Title: A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI-91 in patients with mild to moderate Alzheimer’s Disease
    Medical condition: Mild to moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003272-41 Sponsor Protocol Number: R3918-MG-2018 Start Date*: 2022-05-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) PL (Ongoing) DK (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015170-35 Sponsor Protocol Number: 5137 Start Date*: 2012-01-27
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD)
    Medical condition: Parkinson's disease with mild dementia (PDD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003214-15 Sponsor Protocol Number: VP-AD-302 Start Date*: 2005-12-12
    Sponsor Name:Voyager Pharmaceutical Corporation
    Full Title: A DOUBLE-BLIND PLACEBO- CONTROLLED STUDY OF VP4896 FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE
    Medical condition:
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) LT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000630-30 Sponsor Protocol Number: AC-AD-003 Start Date*: 2015-11-26
    Sponsor Name:AXON NEUROSCIENCE SE
    Full Title: “ADAMANT” A 24-months randomised, placebo-controlled, parallel group, double blinded, multi centre, phase 2 study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s ...
    Medical condition: Alzheimer’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SE (Completed) DE (Completed) SK (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2012-005542-38 Sponsor Protocol Number: MK-8931-019 Start Date*: 2014-03-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment...
    Medical condition: prodromal Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005762-34 Sponsor Protocol Number: MGCDB001 Start Date*: 2021-07-15
    Sponsor Name:Medical University of Lublin
    Full Title: A phase 2 clinical trial assessing the efficacy and safety of adding cladribine for treatment modifying course of seropositive myasthenia gravis
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003151-20 Sponsor Protocol Number: 8931-017 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer?s Disease. (Phase 2/3; Protocol No. MK-8931-017-02) ...
    Medical condition: mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) PT (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002078-30 Sponsor Protocol Number: REDNES06052013 Start Date*: 2013-08-08
    Sponsor Name:Onze-Lieve-Vrouw Ziekenhuis
    Full Title: Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double bl...
    Medical condition: We will compare usual care (neostigmine) with sugammadex for reversal of a moderate rocuronium-induced neuromuscular blockade and assess the effect on diaphragmatic EMG activity of sugammadex versu...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004893-32 Sponsor Protocol Number: CL03-ORY-2001 Start Date*: 2018-04-03
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA